You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 23, 2024

Claims for Patent: 7,132,458

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,132,458

Title:	Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents
Abstract:	This invention features fractionated oxidized carotenoid or retinoid mixtures, and individual components thereof, which are useful as cell-differentiation-inducing, anti-proliferative, anti-metastatic and anti-tumor agents. The mixtures and compounds of the invention can be used alone or in combination with other anticancer agents for the treatment of cancer.
Inventor(s):	Burton; Graham (Ottawa, CA), Daroszewski; Janusz (Ottawa, CA), Phipps; Jenny (Chelsea, CA), Arya; Prabhat (Orleans, CA)
Assignee:	Chemaphor Inc. (Ontario, CA)
Application Number:	10/196,695
Patent Claims:	1. A pharmaceutical composition comprising 2-methyl-6-oxo -2,4-heptadienal, wherein said composition is formulated as a tablet or capsule and wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 2. The pharmaceutical composition of claim 1, wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 1% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 3. The pharmaceutical composition of claim 2, further comprising an anticancer agent selected from mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, uracil mustard, estramustine , mitomycin C, AZQ, thiotepa, busulfan, hepsulfam, carmustine, lomustine, semustine, streptozocin, dacarbazine, cisplatin, carboplatin, procarbazine, methotrexate, trimetrexate, fluouracil, floxuridine, cytarabine, fludarabine phosphate, azacitidine, thioguanine, mercaptopurine, cladribine, allopurine, gemcitabine, pentostatin, vinbiastine, vincristine, etoposide, teniposide, topotecan, irinotecan, camptothecin, 9-aminocamptothecin, paclitaxel, docetaxel, daunorubicin, doxorubicin, dactinomycin, idarubincin, plicamycin, mitomycin, amsacrine, bleomycin, aminoglutethimide, anastrozole, finasteride, ketoconazole, tamoxifen, flutamide, leuprolide, goserelin, imatinib mesylate, Leflunomide, SU5416, SU6668, PTK787, gefitinib , erlotinib hydrochloride , trastuzumab, cetuximab , PKI166, GW2016, EKB-509, EKB -569, MDX-H210, 2C4, MDX-447, ABX-EGF, CI-1033, bevacizumab, IMC-1C11, ZD4190, ZD6474, CEP-701, CEP-751, MLN518, PKC412, 13-cis-retinoic acid, isotretinoin, retinyl palmitate, 4-(hydroxycarbophenyl) retinamide, misonidazole, nitracrine, mitotoxantrone, hydroxyurea, 1-asparginase, interferon alfa, rapamycin, CCI-779, and mitotane. 4. A pharmaceutical pack comprising 2-methyl-6-oxo-2,4-heptadienal and an anticancer agent selected from mechiorethamine, cyclophosphamide, ifosfamide, meiphalan, chiorambucil, uracil mustard, estramustine , mitomycin C, AZQ, thiotepa, busulfan, hepsulfam, carmustine, lomustine, semustine, streptozocin, dacarbazine, cisplatin, carboplatin, procarbazine, methotrexate, trimetrexate, fluouracil, floxuridine, cytarabine, fludarabine phosphate, azacitidine, thioguanine, mercaptopurine, cladribine, allopurine, gemcitabine, pentostatin, vinbiastine, vincristine, etoposide, teniposide, topotecan, irinotecan, camptothecin, 9-aminocamptothecin, paclitaxel, docetaxel, daunorubicin, doxorubicin, dactinomycin, idarubincin, plicamycin, mitomycin, amsacrine, bleomycin, aminoglutethimide, anastrozole, finasteride, ketoconazole, tamoxifen, flutamide, leuprolide, goserelin, imatinib mesylate, Leflunomide, SU5416, SU6668, PTK787, gefitinib, erlotinib hydrochloride, trastuzumab, cetuximab, PKI166, GW2016, EKB-509, EKB-569, MDX-H210, 2C4, MDX-447, ABX-EGF, CI-1033, bevacizumab, IMC-1C11, ZD4190, ZD6474, CEP-701, CEP-751, MLN518, PKC412, 13-cis-retinoic acid, isotretinoin, retinyl palmitate, 4-(hydroxycarbophenyl) retinamide, misonidazole, nitracrine, mitotoxantrone, hydroxyurea, 1-asparginase, interferon alfa, rapamycin, CCI-779, and mitotane, wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl -6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said pharmaceutical pack. 5. The pharmaceutical pack of claim 4, wherein said 2-methyl -6-oxo-2,4-heptadienal and said anticancer agent inhibitor are formulated separately and in individual dosage amounts. 6. A pharmaceutical composition comprising 2-methyl-6-oxo -2,4-heptadienal, wherein said composition is formulated as a powder, nasal drop, or aerosol and wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 7. A pharmaceutical composition comprising 2-methyl-6-oxo -2,4-heptadienal, wherein said composition is formulated for the controlled release of said 2-methyl-6-oxo-2,4-heptadienal and wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl -6-oxo-2,4-heptadienal in said composition. 8. A pharmaceutical composition comprising 2-methyl-6-oxo oxo-2,4-heptadienal, wherein said composition is formulated as a biodegradable nanoparticle, solid lipid nanoparticle, liposome, microsphere, suspension, or emulsion and wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 9. A pharmaceutical composition comprising 2-methyl-6-oxo -2,4-heptadienal and an excipient selected from magnesium stearate, zinc stearate, stearic acid, hydrogenated vegetable oil, hydrogenated naphthalene, talc, silica, lactose, polyoxyethylene-9-lauryl ether, deoxycholate, polyethylene glycol, sucrose, sorbitol, lactide polymer, lactide/glycolide copolymer, ethylene-vinyl acetate copolymer, and polyoxyethylene-polyoxypropylene copolymer, wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 10% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 10. The pharmaceutical composition of any of claims 6 9, wherein .beta.-carotene and oxidation products of .beta.-carotene other than 2-methyl-6-oxo-2,4-heptadienal are less than 1% of the mass of 2-methyl-6-oxo-2,4-heptadienal in said composition. 11. The pharmaceutical composition of claim 10, further comprising an anticancer agent selected from mechiorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, uracil mustard, estramustine , mitomycin C, AZQ, thiotepa, busulfan, hepsulfam, carmustine, lomustine, semustine, streptozocin, dacarbazine, cisplatin, carboplatin, procarbazine, methotrexate, trimetrexate, fluouracil, floxuridine, cytarabine, fludarabine phosphate, azacitidine, thioguanine, mercaptopurine, cladribine, allopurine, gemcitabine, pentostatin, vinblastine, vincristine, etoposide, teniposide, topotecan, irinotecan, camptothecin, 9-aminocamptothecin, paclitaxel, docetaxel, daunorubicin, doxorubicin, dactinomycin, idarubincin, plicamycin, mitomycin, amsacrine, bleomycin, aminoglutethimide, anastrozole, finasteride, ketoconazole, tamoxifen, flutamide, leuprolide, goserelin, imatinib mesylate, Leflunomide, SU5416, SU6668, PTK787, gefitinib, erlotinib hydrochloride, trastuzumab, cetuximab, PKI166, GW2016, EKB-509, EKB-569, MDX-H210, 2C4, MDX-447, ABX-EGF, CI-1033, bevacizumab, IMC-1C11, ZD4190, ZD6474, CEP-701, CEP-751, MLN518, PKC412, 13-cis-retinoic acid, isotretinoin, retinyl palmitate, 4-(hydroxycarbophenyl) retinamide, misonidazole, nitracrine, mitotoxantrone, hydroxyurea, 1-asparginase, interferon alfa, rapamycin, CCI-779, and mitotane.

Details for Patent 7,132,458

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2014-08-10
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2014-08-10
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	02/12/2004	⤷ Try a Trial	2014-08-10
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	03/28/2007	⤷ Try a Trial	2014-08-10
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2014-08-10
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2014-08-10
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.